Related Experiment Video
Updated: Sep 30, 2025
05:15
Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
Published on: July 27, 2022
1.7K
Noncoding RNAs in Cardiac Hypertrophy and Heart Failure
Peilei Lu1, Fan Ding1, Yang Kevin Xiang2
1Department of Pharmaceutical Toxicology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Cells
|March 10, 2022
Summary
Noncoding RNAs (ncRNAs) play crucial roles in heart failure development. This review explores how microRNAs, long noncoding RNAs, and circular RNAs impact cardiac hypertrophy and heart failure pathogenesis.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiology
Background:
- Heart failure represents a significant global health challenge.
- Noncoding RNAs (ncRNAs) are integral to cellular processes and disease, including heart failure.
- ncRNAs are key regulators of cardiac development, stress responses, signaling, and pathological remodeling.
Purpose of the Study:
- To review the critical roles of various ncRNAs in cardiac hypertrophy and heart failure.
- To highlight recent advancements in understanding ncRNAs within cardiovascular disease research.
- To discuss the specific contributions of microRNAs, long noncoding RNAs, and circular RNAs.
Main Methods:
- Literature review of recent studies on ncRNAs in cardiovascular disease.
- Analysis of ncRNA involvement in transcriptional regulation of cardiac function.
- Synthesis of findings on ncRNAs modulating cardiac hypertrophy and heart failure.
Main Results:
- ncRNAs are essential regulators of cardiac physiological and pathological processes.
- MicroRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs) significantly influence cardiac hypertrophy.
- Dysregulation of these ncRNAs contributes to the progression of heart failure.
Conclusions:
- ncRNAs are pivotal in the pathogenesis of heart failure.
- Targeting specific ncRNAs presents potential therapeutic strategies for heart failure.
- Further research into ncRNA mechanisms is crucial for advancing cardiovascular medicine.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
82
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
82
01:17Pathophysiology of Heart Failure
1.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
543
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
543
02:39lncRNA - Long Non-coding RNAs
9.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
78
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
78
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
68
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
68